NovaBridge Biosciences
0VY
Company Profile
Business description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.10 | 29.10 | -0.32% |
| CAC 40 | 8,274.57 | 53.29 | -0.64% |
| DAX 40 | 24,066.70 | 22.48 | 0.09% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,559.58 | 49.48 | -0.47% |
| HKSE | 25,947.32 | 75.00 | 0.29% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 58,134.24 | 256.85 | 0.44% |
| NZX 50 Index | 13,076.58 | 59.32 | 0.46% |
| S&P 500 | 7,022.95 | 55.57 | 0.80% |
| S&P/ASX 200 | 8,978.70 | 32.70 | -0.36% |
| SSE Composite Index | 4,027.21 | 0.58 | 0.01% |